Should I buy or sell Jasper Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares. View JSPR analyst ratings or view top-rated stocks .

What is Jasper Therapeutics' stock price target for 2024?

8 Wall Street research analysts have issued 1 year price objectives for Jasper Therapeutics' shares. Their JSPR share price targets range from $40.00 to $80.00. On average, they predict the company's share price to reach $64.17 in the next year. This suggests a possible upside of 169.4% from the stock's current price. View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts .

How have JSPR shares performed in 2024?

Jasper Therapeutics' stock was trading at $7.89 at the start of the year. Since then, JSPR stock has increased by 201.9% and is now trading at $23.82. View the best growth stocks for 2024 here .

When is Jasper Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our JSPR earnings forecast .

How were Jasper Therapeutics' earnings last quarter?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its earnings results on Monday, March, 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.15.

When did Jasper Therapeutics' stock split?

Jasper Therapeutics's stock reverse split before market open on Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:JSPR

Jasper Therapeutics (JSPR) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free JSPR Stock Alerts

$23.82

-0.35 (-1.45%)

(As of 04/17/2024 ET)

Compare

Today's Range: $23.35
▼
$24.54
50-Day Range: $17.05
▼
$30.00
52-Week Range: $4.00
▼
$31.01

Volume: 71,952 shs
Average Volume: 121,798 shs
Market Capitalization: $358.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $64.17

Get Jasper Therapeutics alerts:

Jasper Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 169.4% Upside
$64.17 Price Target
Short Interest: Healthy
3.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$4.53 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($5.00) to ($4.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

484th out of 913 stocks

Biological Products, Except Diagnostic Industry

72nd out of 134 stocks

3.5

Analyst's Opinion

Consensus Rating
Jasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Jasper Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.84% of the float of Jasper Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Jasper Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Jasper Therapeutics has recently increased by 38.07%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Jasper Therapeutics does not currently pay a dividend.
Dividend Growth
Jasper Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JSPR.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Jasper Therapeutics this week, compared to 2 articles on an average week.
Search Interest
28 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
7 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jasper Therapeutics insiders have bought 18,947.32% more of their company's stock than they have sold. Specifically, they have bought $4,532,500.00 in company stock and sold $23,796.00 in company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Jasper Therapeutics is held by insiders.
Percentage Held by Institutions
79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Jasper Therapeutics are expected to grow in the coming year, from ($5.00) to ($4.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jasper Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jasper Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Jasper Therapeutics has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

JSPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JSPR Stock News Headlines

April 13, 2024 | americanbankingnews.com

Analyzing Finch Therapeutics Group (NASDAQ:FNCH) and Jasper Therapeutics (NASDAQ:JSPR)

April 2, 2024 | globenewswire.com

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 28, 2024 | msn.com

RBC starts Jasper Therapeutics at outperform, cites market opportunity

March 21, 2024 | globenewswire.com

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment

March 20, 2024 | finance.yahoo.com

Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42% ownership, institutions own 26%

March 19, 2024 | globenewswire.com

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 16, 2024 | finance.yahoo.com

JSPR Jul 2024 40.000 call

March 15, 2024 | finanznachrichten.de

Jasper Therapeutics, Inc.: New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

March 15, 2024 | globenewswire.com

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

March 14, 2024 | msn.com

Entrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85M

March 11, 2024 | finance.yahoo.com

JSPR Oct 2024 30.000 call

March 10, 2024 | finance.yahoo.com

JSPR Oct 2024 17.500 call

March 10, 2024 | finance.yahoo.com

JSPR Apr 2024 35.000 call

March 6, 2024 | finance.yahoo.com

JSPR Mar 2024 22.500 put

March 6, 2024 | investorplace.com

JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Jasper Therapeutics’ Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatment

March 4, 2024 | finanznachrichten.de

Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

March 4, 2024 | globenewswire.com

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

March 3, 2024 | finance.yahoo.com

JSPR Mar 2024 15.000 put

February 27, 2024 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)

February 27, 2024 | markets.businessinsider.com

Buy Rating on Jasper Therapeutics Highlighting Briquilimab’s Potential in Chronic Urticaria Treatment

February 26, 2024 | globenewswire.com

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

February 23, 2024 | globenewswire.com

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 23, 2024 | finance.yahoo.com

JSPR Mar 2024 20.000 call

See More Headlines

Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:JSPR
CUSIP: N/A
CIK: 1788028
Web: jaspertherapeutics.com
Phone: 650-549-1400
Fax: N/A
Employees: 45
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $64.17
High Stock Price Target: $80.00
Low Stock Price Target: $40.00
Potential Upside/Downside: +169.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-64,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.21%
Return on Assets: -55.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.19
Quick Ratio: 7.19

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.03 per share
Price / Book: 3.39

Miscellaneous

Outstanding Shares: 15,060,000
Free Float: 14,477,000
Market Cap: $358.73 million
Optionable: Optionable
Beta: 2.22

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Ronald A. Martell (Age 62)
President, CEO & Director
Comp: $892.45k
Dr. Judith Anne Shizuru M.D. (Age 68)
Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
Comp: $291.25k
Mr. Jeetinder Singh Mahal M.B.A. (Age 52)
Chief Operating Officer
Comp: $579.46k
Mr. Herbert C. Cross (Age 52)
CFO & Corporate Secretary
Dr. Luca Di Noto Ph.D.
Senior Vice President of Technical Operations
Mr. David Ku M.D.
Vice President of Corporate Development, Portfolio Strategy & Management
Mr. Matthew Ford
Vice President of Human Resources
Dr. Wendy Pang M.D.
Ph.D., Senior Vice President of Research & Translational Medicine
Dr. Edwin Jonathan Tucker M.D. (Age 52)
Chief Medical Officer
Ms. Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JSPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings or view top-rated stocks.
What is Jasper Therapeutics' stock price target for 2024?: 8 Wall Street research analysts have issued 1 year price objectives for Jasper Therapeutics' shares. Their JSPR share price targets range from $40.00 to $80.00. On average, they predict the company's share price to reach $64.17 in the next year. This suggests a possible upside of 169.4% from the stock's current price.
View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts.
How have JSPR shares performed in 2024?: Jasper Therapeutics' stock was trading at $7.89 at the start of the year. Since then, JSPR stock has increased by 201.9% and is now trading at $23.82.
View the best growth stocks for 2024 here.
When is Jasper Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our JSPR earnings forecast.

How were Jasper Therapeutics' earnings last quarter?: Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its earnings results on Monday, March, 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.15.
When did Jasper Therapeutics' stock split?: Jasper Therapeutics's stock reverse split before market open on Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
How do I buy shares of Jasper Therapeutics?: Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JSPR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Jasper Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Jasper Therapeutics Stock (NASDAQ:JSPR)

JSPR Stock Price History

JSPR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

JSPR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™